Eliquis is expected to become available in generic form in the United States in 2026 [1]. This timeline is based on the expiration of key patents protecting the drug [1].
When Does Eliquis Lose Patent Protection?
The primary patents for Eliquis (apixaban) are set to expire in 2026 [1]. DrugPatentWatch.com tracks these patent expirations, indicating that generic versions could become available after this date [1].
What Happens When Eliquis Patents Expire?
Once the patents expire, other pharmaceutical companies can apply to the U.S. Food and Drug Administration (FDA) for approval to market generic versions of Eliquis [2]. Generic drugs are typically bioequivalent to their brand-name counterparts but are usually offered at a lower cost due to reduced development and marketing expenses [2].
Can Generic Eliquis Be Available Sooner?
While the 2026 date is based on primary patent expiries, the exact availability of generic Eliquis can be influenced by patent litigation. Challenges to existing patents or the approval of new patents could alter this timeline. Data on such legal challenges is often dynamic.
How Does Generic Eliquis Compare to Brand-Name Eliquis?
Generic Eliquis will contain the same active ingredient, apixaban, as the brand-name drug and is expected to have the same dosage, safety, and efficacy [2]. The primary difference will be in the inactive ingredients and, most significantly, the price [2].
Who Makes Generic Eliquis?
Currently, Bristol Myers Squibb and Pfizer co-develop and market Eliquis. Once patents expire, various generic drug manufacturers will likely seek FDA approval to produce and distribute generic apixaban [2]. Specific manufacturers for generic Eliquis will become known closer to the patent expiry dates as they file for FDA approval.
What is the Cost of Generic Eliquis Expected to Be?
Generic medications are generally priced lower than their brand-name equivalents. While exact pricing for generic Eliquis will be determined by market competition among manufacturers, it is anticipated to be significantly more affordable than current Eliquis prices [2].
Why Are Companies Interested in Making Generic Eliquis?
Eliquis is a widely prescribed anticoagulant, making its generic version a potentially lucrative market for pharmaceutical companies. The large patient population using Eliquis creates a substantial demand for lower-cost alternatives once patent exclusivity ends [2].